Navigation Links
First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP
Date:12/12/2007

Progress of Phase I Programme With Oral Iclaprim "Rolling" NDA for Intravenous Iclaprim in cSSSI; Electronic Submission of

First Modules due Before Year-end 2007

REINACH, Switzerland, December 12 /PRNewswire-FirstCall/ -- Arpida Ltd (SWX: ARPN) announced today the enrolment and dosing of the first patients in the Phase II clinical study with intravenous iclaprim in the treatment of hospital-acquired pneumonia (HAP) / ventilator-associated pneumonia (VAP) / healthcare-associated pneumonia (HCAP).

In addition, Arpida announced results of a Phase I study with oral iclaprim. The primary aim of the study was to assess the safety and tolerability of single ascending doses of an oral capsule formulation of iclaprim in healthy volunteers.

Moreover, Arpida today announced that the first modules of the New Drug Application (NDA) for intravenous iclaprim in its first indication, cSSSI, are ready and will be filed before year-end 2007. The filing of the NDA package is expected to be completed by the end of February 2008.

First patients enrolled in Phase II trial with intravenous iclaprim in HAP/VAP/HCAP

Patient recruitment has started and several additional clinical centres are expected to start recruiting within the next few weeks. The trial remains on track for completion in 2008.

HAP/VAP/HCAP as a potential second indication could substantially enhance iclaprim's prospects as a potent novel therapy against multi-drug resistant bacteria. In the area of pneumonia, the need for new drugs addressing MRSA-infections is particularly pressing.

The Phase II trial is designed as a multi-centre, randomised, double-blind, comparative study. The efficacy and safety of two different dosing regimens of iclaprim will be compared to the current standard of care vancomycin. More than 130 patients will be enrolled. Patients will be treated for 7-14 days and a Test-of-Cure (TOC) visit will be performed 7-14
'/>"/>

SOURCE Arpida Ltd
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
3. Kewaunee Scientific Announces First Quarter Results and Quarterly Dividend
4. Genmab Announces 2007 First Half Year Results
5. Pharsight Achieves First License Sale for Public-Source Database
6. Novare Announces First Ever Single Port Laparoscopic Kidney Removal (Nephrectomy) Using RealHand(TM) HD Instruments
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. China Medical Technologies Reports First Quarter Financial Results
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
11. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... SCHOFIELD, Wis. , May 23, 2013 /PRNewswire/ ... a researcher, developer, and marketer of over-the-counter (OTC) ... re-issued its research opinion on the company based ... Highlights , Non-Prescription, All Natural Product ... Show the Product Outperforms #1 Prescription Competitor ...
(Date:5/23/2013)... Calif. , May 23, 2013  Saddleback Memorial ... recently became the first hospital on the West ... technology. This new surgical option provides women with a ... Marc Winter , M.D., a ... and surgeon and medical director of minimally invasive surgery ...
(Date:5/23/2013)... Northwest Biotherapeutics (NASDAQ: NWBO ) ... personalized immune therapies for solid tumor cancers, announced today ... American Society Of Clinical Oncology (ASCO) meeting in ... in immune therapy.  (Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO ) ... pre-eminent conference focused on clinical treatment of cancer, with ...
(Date:5/23/2013)... May 23, 2013 Pusan National University ... private biotherapeutics and contract research company focused on ... cancer, announced today a publication reporting the induction ... the oncolytic and immunotherapeutic vaccinia JX-594 (pexastimogene devacirepvec; ... published in the May 15 th , 2013 ...
Breaking Biology Technology:PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 2Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 3NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 2Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 3
... EDMONTON, Aug. 12 /PRNewswire-FirstCall/ - BioMS Medical ... of multiple sclerosis (MS), today,announced financial and operational ... BioMS Medical, in partnership with Eli Lilly and ... the treatment of MS,undergoing pivotal trials in Canada, ...
... ChromaDex,Corporation, (OTC Bulletin Board: CDXC) a leader ... financial results for the,second quarter of 2008. On ... Accepted Accounting Principles (GAAP), ChromaDex announced a,net loss ... for the,three months ended June 28, 2008., ...
... to the previous Quarter ... per Month, BEDFORD, Mass., Aug. 12 Insulet Corporation,(Nasdaq: ... its OmniPod(R),Insulin Management System, today announced financial results for the ... quarter 2008 reported revenue increased 131% to $7.4 million,compared to ...
Cached Biology Technology:BioMS Medical Announces Second Quarter 2008 Results 2BioMS Medical Announces Second Quarter 2008 Results 3BioMS Medical Announces Second Quarter 2008 Results 4BioMS Medical Announces Second Quarter 2008 Results 5ChromaDex Announces Second Quarter 2008 Financial Results 2ChromaDex Announces Second Quarter 2008 Financial Results 3Insulet Reports Second Quarter 2008 Results 2Insulet Reports Second Quarter 2008 Results 3Insulet Reports Second Quarter 2008 Results 4Insulet Reports Second Quarter 2008 Results 5Insulet Reports Second Quarter 2008 Results 6Insulet Reports Second Quarter 2008 Results 7Insulet Reports Second Quarter 2008 Results 8
(Date:5/23/2013)... HOUSTON (May 23, 2013) A new report ... responsible for helping pupils engage in at least 60 ... school day. , No more than half of American ... hour of vigorous or moderate intensity physical activity daily, ... , "Because children are in school for nearly half ...
(Date:5/23/2013)... the interplay of brain chemicals which help us pay ... BBSRC. , By changing the way neurons respond ... these changes can affect the strength of a neuronal ... response. , Lead author Alex Thiele, Professor ... you can make yourself better heard by speaking louder ...
(Date:5/22/2013)... in fuel cell powered buses, including a team ... electrode degradation processes and bus membrane durability. , ... degradation stressors in the operating cycle of the ... of the study, led by SFU graduate student ... study at Burnaby-based Ballard Power Systems and funded ...
Breaking Biology News(10 mins):Schools should provide students with daily physical activity, IOM recommends 2Tests lead to doubling of fuel cell life 2
... has been a confirmed sighting of one of the rarest and ... Vietnam. The Government of the Lao People,s Democratic Republic (also ... in the central province of Bolikhamxay captured a saola and brought ... later, but was photographed while still alive. This ...
... The diversity of life that can be seen in environments ... blooms of the Mohave Desert is awe-inspiring. But this diversity ... had just stayed in the water with their green algal ... adapt to this new "hostile" environment, and in turn helped ...
... 2010 UC Irvine researchers have deciphered how lowly fruit ... time. The findings, reported in the Sept. 15 online issue ... beings evolve the same way simpler organisms do and could ... and other products. "This is actually decoding the key ...
Cached Biology News:Asian 'unicorn' photographed for first time in over 10 years 2Asian 'unicorn' photographed for first time in over 10 years 3Learning to live on land: How some early plants overcame an evolutionary hurdle 2UCI scientists decode genomes of sexually precocious fruit flies 2
... handy dispensers save space and ... hats, and other garb. They ... bins for small parts used ... Clear acrylic. Many other sizes ...
... Microarrays designed for genome-wide microRNA expression profiling ... Paraflo microfluidic on-chip synthesis platform. These microarrays ... microRNA Expression Profiling Service. Probe ... all known cow microRNAs (108 unique mature ...
... the legendary MSn performance of the LTQ, ... through Thermo Scientifics innovations in ion trap ... the only mass spectrometer that offers multiple ... Pulsed Q Collision Induced Dissociation (PQD) is ...
... Solomon's laboratory animal infusion kits reduce the ... infusion study while providing sterile equipment to ... includes everything you need for one animal, ... and tethers will be cut to the ...
Biology Products: